The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    High-dose probiotic + prebiotic to treat Crohn’s disease

    Earlier study results have been inconsistent. In this study, researchers from Nippon Medical School in Tokyo use higher doses to treat active Crohn’s disease (CD).

    First, the details.

    • 10 adults with active CD but no history of surgery for CD were studied for 13 months.
    • Their main symptoms were diarrhea and abdominal pain that did not respond to initial treatment of aminosalicylates and prednisolone.
    • Synbiotic therapy consisted of probiotics (75 billion colony forming units [CFU] daily) and prebiotics (psyllium 9.9 g daily).
    • Probiotics mainly comprised Bifidobacterium and Lactobacillus.
    • Patients were free to adjust their intake of probiotics or prebiotics.

    By the end of therapy, each patient had taken about 45 billion CFU daily probiotic dose; 6 patients took an additional 8 g daily psyllium dose.

    And, the results.

    • 7 had improved symptoms following combined pre/probiotic therapy.
    • Crohn’s Disease Activity Index (CDAI), and the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score were significantly reduced after therapy.
    • 6 patients had a complete response.
    • One had a partial response
    • 3 were non-responders.
    • 2 patients were able to discontinue their prednisolone therapy, while 4 decreased their intake.
    • There were no adverse events.

    The bottom line?
    This study addresses an important issue in pro/pre/synbiotic research — dosing. The results were positive and support more research in this area.

    8/16/07 22:31 JR

    Leave a Comment

    You must be logged in to post a comment.